(Q53976269)

23 May 2018

title

Q10 therapy in patients with idiopathic Parkinson's disease. (English)

1 reference

23 May 2018

1 reference

E Strijks

1

1 reference

23 May 2018

H P Kremer

series ordinal

2

1 reference

23 May 2018

M W Horstink

series ordinal

3

1 reference

23 May 2018

publication date

1 January 1997

1 reference

23 May 2018

Molecular Aspects of Medicine

published in

1 reference

23 May 2018

volume

18 Suppl

1 reference

23 May 2018

page(s)

S237-40

1 reference

23 May 2018

Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

7 January 2021

31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

7 January 2021

Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

7 January 2021

Isoprenoids in aging and neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

7 January 2021

Regional distribution of ubiquinones and tocopherols in the mouse brain: lowest content of ubiquinols in the substantia nigra

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

7 January 2021

Ubiquinone protects cultured neurons against spontaneous and excitotoxin-induced degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

7 January 2021

Assessment of coenzyme Q10 tolerability in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

7 January 2021

Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

7 January 2021

Which risk factors predict the levodopa response in fluctuating Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

1 reference

7 January 2021

Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

7 January 2021

Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

7 January 2021

Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

7 January 2021

Mechanism of the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP+), the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

7 January 2021

Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0098-2997%2897%2900008-3

7 January 2021

10.1016/S0098-2997(97)00008-3

Identifiers

DOI

1 reference

23 May 2018

1 reference

23 May 2018